PYCARD and Alzheimer disease: While this strategy has not been thoroughly tested in AD so far, drug-targeting ASC speck formation could potentially mitigate inflammasome-mediated pathology in AD, as observed in AD mice models with ASC deficiency (Asc−/−) [168,170].